Press Releases.

Month Year

Month Year

Investor Alerts

November 07, 2024

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
October 08, 2024

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
August 28, 2024

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
August 08, 2024

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
August 06, 2024

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
July 09, 2024

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
June 24, 2024

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
June 04, 2024

Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes
May 16, 2024

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
May 09, 2024

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

Show per page